M en with previously “untreatable” prostate cancer are being kept alive by a new drug in what experts believe may be a breakthrough for patients with the worst form of the disease.
A British trial has for the first time shown that state-of-the art immunotherapy can be used to target prostate tumours.
The study at the Royal Marsden Hospital in London found more than a third of men who had run out of existing options were still alive and one in ten had not seen their tumours grow after a year of taking Pembrolizumab, which targets a gateway helps the immune system to attack cancer cells.
Read more
Comments are closed.